SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is experiencing high volatility as traders react to ongoing speculation regarding its IoT ecosystem and Layer-2 data integration, while community sentiment remains sharply divided between long-term holders betting on Japanese tech partnerships and skeptics focused on declining price momentum.

Green Satoshi Token

Community members are actively monitoring technical indicators and volume spikes, viewing the current price action as a potential coil-up for a significant breakout. While some remain skeptical about long-term supply dynamics, bulls are pointing to broader altcoin momentum and institutional interest as catalysts that could drive a sustained upward trend.

ARK ETF Trust - ARK Space & Defense Innovation ETF

ARK Space Exploration & Innovation ETF

The ARK Space Exploration & Innovation ETF is generating intense community interest driven by anticipation surrounding a potential SpaceX IPO and the broader, long-term growth trajectory of the space sector. Investors are actively debating the fund's strategy and composition, viewing it as a strategic, albeit volatile, play on the future of space infrastructure, defense technology, and AI integration.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy community is actively mobilizing around the MULN crypto token, with supporters pushing for a resurgence similar to previous market rallies while critics warn of pump-and-dump mechanics. The conversation is heavily driven by retail coordination on social platforms, alongside community calls for new buying pressure to sustain the token's momentum.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

The GIGA community is actively discussing the coin's long-term potential as an asymmetric opportunity, fueled by ongoing engagement with the Giga Fitness brand and recent real-world visibility. While some investors remain cautious about volatility, many are advocating for a disciplined dollar-cost averaging strategy, drawing parallels to previous market cycles and highlighting the strength of the GigaChad meme culture.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as the community anticipates potential utility shifts and technical breakouts, with active discussions focusing on a possible 'DogeOS' release and bullish chart patterns. Enthusiasts and skeptics continue to debate the token's long-term value and its correlation with broader market movements and macroeconomic sentiment.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

The VVV (Venice Token) community is highly bullish, driven by the AI narrative, upcoming token burns, and a perceived supply crunch due to its low circulating supply and staking activity. Traders are actively discussing the token's potential to reach double-digit price levels as a decentralized AI play, often citing new platform features and the potential for a major exchange listing as catalysts for future price appreciation.

Polygon

Polygon is seeing renewed interest driven by strategic shifts toward institutional payment infrastructure and real-world asset tokenization, though the community remains polarized between long-term bulls highlighting network activity and frustrated traders focused on price stagnation. Investors are actively debating the impact of recent network upgrades, increased stablecoin volume, and potential regulatory catalysts on its long-term growth potential.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is seeing strong retail interest as investors weigh its aggressive U.S. expansion plans and AI infrastructure investments against a period of recent price consolidation. The community is actively debating whether the stock's transition year and institutional positioning represent a prime buying opportunity or a test of patience ahead of upcoming earnings.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

ARK Innovation ETF is trending as investors debate the impact of Cathie Wood's shifting portfolio strategy, specifically her recent exits from high-performing tech stocks versus aggressive entries into speculative assets. The community remains divided, with some users highlighting historical performance and volatility concerns while others monitor institutional flows and institutional block trades for potential reversal signals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates

The Joint (JYNT) delivered earnings and revenue surprises of +166.67% and +5.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CorMedix Inc (NASDAQ:CRMD) Receives Consensus Rating of "Moderate Buy" from Analysts

CorMedix Inc (NASDAQ:CRMD - Get Free Report) has been given a consensus rating of 'Moderate Buy' by the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One...

210,831 Shares in CorMedix Inc $CRMD Acquired by Del Sette Capital Management LLC

Del Sette Capital Management LLC acquired a new position in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund...

CorMedix (CRMD) Expected to Announce Earnings on Wednesday

CorMedix (NASDAQ:CRMD) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

CorMedix (NASDAQ:CRMD) Earns Market Outperform Rating from Citizens Jmp

Citizens Jmp restated a "market outperform" rating and set a $19.00 price target on shares of CorMedix in a research note on Tuesday...

CorMedix (NASDAQ:CRMD) Price Target Raised to $14.00

Leerink Partners boosted their price objective on shares of CorMedix from $13.00 to $14.00 and gave the stock an "outperform" rating in a research note on Tuesday...

CorMedix (NASDAQ:CRMD) Price Target Raised to $15.00

Needham & Company LLC raised their price target on shares of CorMedix from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Monday...

<ul class="summary-bullets"><li>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections.</li><li>Rezzayo is already approved in the U.S. for the treatment of candidemia and invasive candidiasis in adults.</li><li>The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.</li></ul>Shares of CorMedix Therapeutics (CRMD) rose 2% on Monday after the company announced positive results from its late-stage trial evaluating its antifungal drug Rezzayo to prevent invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Allogeneic hematopoietic stem cell transplantation is a curative procedure for high-risk blood cancers and marrow diseases, where healthy blood-forming cells from a donor replace a patient's diseased marrow. Patients undergoing the procedure face prolonged periods where their immunity is not strong enough to ward off infections from fungi, including candida, aspergillus, and pneumocystis.Rezzayo is already approved in the U.S. for the treatment of fungal infections, candidemia, and invasive candidiasis in adults. The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.<h2 class="st-heading-2">Trial Takeaways</h2>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections, the company said. Fungal-free survival at day 90 was 60.7% in the Rezzayo group versus 59.0% in the group that received a standard antimicrobial regimen, it added.Furthermore, the drug was well tolerated with a safety profile showing a favorable benefit/risk profile in the patient population, the company said, while adding that the drug also demonstrated fewer interactions with other drugs and discontinuations due to toxicity.CorMedix now expects to have a meeting with the U.S. Food and Drug Administration in the coming months before submitting an application for the drug for the indication. The company expects to file the application in the second half of 2026 based on the trial results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CRMD jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels. According to internal data, retail chatter around the stock jumped 1400% over the past day.A Stocktwits user expressed optimism for the stock rising into earnings while adding that “today was great news.”<stembedurl>https://www.stocktwits.com/S2730/message/651521499</stembedurl>Another user expressed muted enthusiasm, opining that the results, though good, are not “transformative.”<stembedurl>https://www.stocktwits.com/ReturnOfEsquire/message/651515352</stembedurl> <a href="https://stocktwits.com/symbol/CRMD">CRMD stock</a> has fallen 17% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sndk-stock-surges-nearly-8-to-hit-fresh-record-high-what-s-behind-the-investor-optimism-april-27/cZBND2dReP8">SNDK Stock Surges Nearly 8% To Hit Fresh Record High – What’s Behind The Investor Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market 

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 

Equity

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 


CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

CorMedix says Phase 3 ReSPECT data show rezafungin is non-inferior in fungal prevention, supporting FDA filing plans and a $2 billion market outlook.read more...

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.34	--	--	N/A
Q4 '25	$0.82	$0.16	-80.40%	MISSED
Q3 '25	$0.63	$1.26	98.65%	BEAT
Q2 '25	$0.19	$0.29	54.96%	BEAT
Q1 '25	$0.26	$0.30	15.38%	BEAT

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest CRMD News

CRMDCorMedix Inc